numares HEALTH
Numares Health, founded in 2006, develops advanced biomarker tests for diagnosing and monitoring diseases related to metabolic dysfunction, including chronic kidney, liver, and cardiac conditions.
Profile
Develops advanced diagnostic tests for metabolic diseases using nuclear magnetic resonance technology.
Numares Health, founded in 2006, develops advanced biomarker tests for diagnosing and monitoring diseases related to metabolic dysfunction, including chronic kidney, liver, and cardiac conditions. The company leverages nuclear magnetic resonance (NMR) spectroscopy and machine learning to identify specific metabolites from a single serum sample, enabling precise diagnostics. Its flagship product, the AXINON® System, integrates diagnostic testing algorithms into NMR spectroscopy and has received FDA clearance for certain applications.
Numares Health has expanded its regulatory approvals internationally, including in Malaysia, and continues to develop new diagnostic tools. The company’s focus on multiplex metabolomics allows for personalized assessments, which are increasingly critical in precision medicine. Financially, Numares Health has seen steady growth, supported by strategic regulatory milestones and market expansion.
Recent developments include the FDA clearance of its cardiovascular diagnostic test and the launch of its kidney function assay in the EU. The company’s innovative approach positions it as a key player in the diagnostic space, particularly in addressing unmet needs in metabolic disease management.
Who buys this
- Hospitals and healthcare providers
- Clinical laboratories
- Pharmaceutical companies
- Research institutions
- Patients with metabolic diseases
Strengths and what to watch
Strengths
- FDA-cleared AXINON® System for cardiovascular diagnostics
- International regulatory approvals, including in Malaysia
- Innovative use of NMR spectroscopy and machine learning
Watch for
- Dependence on regulatory approvals for market expansion
- Competition from established diagnostic companies
- Potential challenges in scaling production and distribution
Recent moves
- 7mo ago New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients
- 10mo ago Numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System
- 1y ago FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform
Key Information
- Founded
- 2006
Frequently Asked Questions
What does Numares Health specialize in?
Numares Health develops advanced diagnostic tests for metabolic diseases like kidney, liver, and cardiac conditions. Using nuclear magnetic resonance (NMR) spectroscopy and machine learning, they analyze metabolites from serum samples. Their FDA-cleared AXINON® System enables precise, personalized diagnostics for improved disease management.
How does Numares Health's diagnostic technology work?
Numares Health combines NMR spectroscopy with machine learning to identify disease-specific metabolic patterns. Their platform analyzes biomarkers from a single blood sample, detecting subtle metabolic changes. This approach allows for early diagnosis and monitoring of conditions like cardiovascular disease and kidney dysfunction without invasive procedures.
What recent FDA approvals has Numares Health received?
In 2025, Numares Health received FDA clearance for its cardiovascular diagnostic test and core technology platform. These approvals validate their AXINON® System's clinical utility, enabling healthcare providers to implement advanced metabolic diagnostics for improved patient care and disease management.
Can Numares Health tests detect kidney transplant rejection?
Yes, Numares Health developed a biomarker test for early detection of kidney transplant rejection in living-donor recipients. Published in Frontiers in Medicine (2026), this non-invasive method analyzes metabolic signatures, offering clinicians a reliable tool for timely intervention and improved transplant outcomes.
Where is Numares Health expanding internationally?
Numares Health has entered the ASEAN market with regulatory approval in Malaysia. This expansion includes deployment of their AXINON® LDLp Test System, demonstrating their global growth strategy and commitment to making advanced metabolic diagnostics available worldwide.
Who uses Numares Health's diagnostic systems?
Hospitals, clinical labs, and research institutions utilize Numares Health's systems for metabolic disease diagnosis. Pharmaceutical companies also partner for clinical trials. Their technology serves patients needing precise diagnostics for kidney, liver, and cardiovascular conditions, supporting personalized treatment approaches.
Sources
- www.numares.com — Recent publication in Frontiers in Medicine
- www.numares.com — ASEAN market entry and regulatory approval
- www.numares.com — FDA clearance of cardiovascular diagnostic test
- www.numares.com — Media feature on Optimum TV